GN-HEARING
GN Hearing, the global leader in hearing aid technology, today announced the introduction of ReSound Assist Live, a real-time video-enabled hearing care service. At a time when elderly, more vulnerable populations are advised to stay home, this innovative telehealth solution enables people, from the comfort and safety of their home, to connect with their hearing care professional for new hearing aids and care remotely.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200402005306/en/
GN Hearing recognizes that COVID-19 may seriously affect people who use hearing aids due to stricter social distancing measures, ultimately affecting many people’s wellbeing and mental health. Telehealth services can make an important difference in helping people stay connected with loved ones and informed on rapidly changing events while staying at home. People do not have to sacrifice their hearing and can get the help they need to hear better.
With the launch of ReSound Assist Live, people can now have new hearing aids adjusted remotely by their hearing care professional via new at-home video consultations without physically going to a clinic. Additionally, in these difficult times, hearing care professionals can provide new hearing aids for those who have recently completed a hearing test. In collaboration with HearX, a digital health care company focused on mobile hearing screening, testing and video otoscopy, hearing care professionals in the US can also offer drive-through or at-home hearing tests and receive adjustments and counseling via ReSound Assist Live.
“At this critical time, GN Hearing is as committed as always to helping the hearing community where it’s most needed. For many people, staying in touch with loved ones on the phone and online demands great hearing abilities, so getting access to hearing care support is crucial, particularly for those in self-isolation when communicating is imperative for an individual’s wellbeing,” says Gitte Aabo, CEO and President of GN Hearing.
ReSound Assist Live is an update to ReSound Assist, which already lets people request and receive adjustments to their hearing aids remotely, but the new telehealth tech goes further, enabling live video consultations with hearing care professionals for support wherever they are. This allows in-person support over live video and remote fitting of hearing aids all via the ReSound Smart 3D™ app.
“We expect that the introduction of ReSound Assist Live will help more hearing aid users and their hearing care professionals connect via our innovative remote solutions that work for them, regardless of what’s going on in their lives, how much mobility they have during this difficult time, and in the future,” Gitte Aabo continues.
ReSound Assist Live is available on April 2, 2020 in the US, Canada, the U.K., Germany, Australia, New Zealand and Singapore, and globally from May 1. At-home and drive-through hearing tests will be offered shortly in the US.
- ENDS -
NOTES TO EDITORS
ReSound Assist Live enables individualized care from anywhere
New ReSound Assist Live is an extension of the existing ReSound Assist remote fine-tuning services and can be accessed via video call on the ReSound Smart 3D app. It is the only fitting software which offers comprehensive live video and remote adjustment options.
ReSound Assist already lets people request and receive adjustments to their hearing aids remotely, but ReSound Assist Live goes further, enabling them to speak directly to their hearing care professional over a live link. This means they can benefit from instant access to the highest level of care at a convenient time and place.
About ReSound
ReSound hearing aids, available from leading hearing care professionals, have set worldwide standards for quality and intuitive technology. ReSound was the first hearing aid brand to be Made for iPhone and pioneered the development of 2.4 GHz wireless technology. The introduction of the sixth generation of this technology with ReSound LiNX QuattroTM demonstrates that ReSound is the absolute leader in the industry. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.
About GN Group
The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com, get to know our innovation and leadership , and connect with us on LinkedIn , Facebook and Twitter .
© 2020 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200402005306/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
Macnica Appoints Sebastien Dignard as CEO of Atlantic Region to Accelerate Global Component-to-Solutions and Vertical Strategy5.1.2026 12:00:00 CET | Press release
Macnica leader to strengthen cross-regional collaboration across the Americas and Europe Macnica Inc. today announced the promotion of Sebastien Dignard to chief executive officer of the company’s Atlantic region. In this role, Dignard will lead Macnica’s business across North America, Europe and South America, accelerating the company’s component-to-solutions strategy and strengthening cross-regional collaboration to deliver long-term value for customers and partners across key verticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105529342/en/ Sebastien Dignard, CEO, Macnica Atlantic Region Dignard previously served as president of Macnica Americas for two years where he led the organization through a period of growth and transformation across semiconductors, imaging, networking and advanced technologies. Under his leadership, the company shifted from a focus on individual components to value-driven solutions, ecosy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom